TITLE

Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIVUnrelated Mortality

AUTHOR(S)
Brinkhof, Martin W. G.; Boulle, Andrew; Weigel, Ralf; Messou, Eugène; Mathers, Colin; Orrell, Catherine; Dabis, François; Pascoe, Margaret; Egger, Matthias
PUB. DATE
April 2009
SOURCE
PLoS Medicine;Apr2009, Vol. 6 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Mortality in HIV-infected patients who have access to highly active antiretroviral therapy (ART) has declined in sub-Saharan Africa, but it is unclear how mortality compares to the non-HIV-infected population. We compared mortality rates observed in HIV-1-infected patients starting ART with non-HIV-related background mortality in four countries in sub-Saharan Africa. Methods and Findings: Patients enrolled in antiretroviral treatment programmes in Côte d'Ivoire, Malawi, South Africa, and Zimbabwe were included. We calculated excess mortality rates and standardised mortality ratios (SMRs) with 95% confidence intervals (CIs). Expected numbers of deaths were obtained using estimates of age-, sex-, and country-specific, HIV-unrelated, mortality rates from the Global Burden of Disease project. Among 13,249 eligible patients 1,177 deaths were recorded during 14,695 person-years of follow-up. The median age was 34 y, 8,831 (67%) patients were female, and 10,811 of 12,720 patients (85%) with information on clinical stage had advanced disease when starting ART. The excess mortality rate was 17.5 (95% CI 14.5-21.1) per 100 person-years SMR in patients who started ART with a CD4 cell count of less than 25 cells/ml and World Health Organization (WHO) stage III/IV, compared to 1.00 (0.55-1.81) per 100 person-years in patients who started with 200 cells/ml or above with WHO stage I/II. The corresponding SMRs were 47.1 (39.1-56.6) and 3.44 (1.91-6.17). Among patients who started ART with 200 cells/ml or above in WHO stage I/II and survived the first year of ART, the excess mortality rate was 0.27 (0.08-0.94) per 100 person-years and the SMR was 1.14 (0.47-2.77). Conclusions: Mortality of HIV-infected patients treated with combination ART in sub-Saharan Africa continues to be higher than in the general population, but for some patients excess mortality is moderate and reaches that of the general population in the second year of ART. Much of the excess mortality might be prevented by timely initiation of ART.
ACCESSION #
45628350

 

Related Articles

  • Forecasting antiretroviral and diagnostic needs.  // WHO Drug Information;2005, Vol. 19 Issue 2, p129 

    Forecasts the accessibility of people with HIV/AIDS to antiretrovirals and diagnostics. Efforts of the World Health Organization to provide treatment to people with HIV/AIDS; Factors that are essential to the success of the WHO initiative; Examination of the best practices and problems in...

  • Scaling Up Treatment – Why We Can't Wait. Kim, Jim Yong; Gilks, Charlie // New England Journal of Medicine;12/1/2005, Vol. 353 Issue 22, p2392 

    The article presents the author's views on antiretroviral treatment programs for people living with the human immunodeficiency virus (HIV) and AIDS. HIV infection has largely become a manageable, chronic condition in countries rich in resources because of the availability of combination-drug...

  • Number of people with HIV on ART climbs to more than 5 million.  // Infectious Diseases in Children;Aug2010, Vol. 23 Issue 8, p21 

    This article reports on the increase in the number of people with human immunodeficiency virus (HIV) who initiated antiretroviral therapy in 2009, according to the World Health Organization (WHO).

  • Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study. Muzah, B. P.; Takuva, S.; Maskew, M.; Delany-Moretlwe, S. // Southern African Journal of HIV Medicine;Nov2012, Vol. 13 Issue 4, p168 

    Background. The therapeutic goal of antiretroviral therapy (ART) is sustained immune recovery and viral suppression. However, some patients experience poor CD4 cell count responses despite achieving viral suppression. Such discordant immune responses have been associated with poor clinical...

  • Quality of life of People living with HIV and AIDS attending the Antiretroviral Clinic, University College Hospital, Nigeria. Folasire, Oluyemisi F.; Irabor, Achiaka E.; Folasire, Ayorinde M. // African Journal of Primary Health Care & Family Medicine;2012, Vol. 4 Issue 1, p1 

    Background: Quality of life (QOL) is an important component in the evaluation of the well-being of people living with HIV and AIDS (PLWHA), especially with the appreciable rise in longevity of PLWHA. Moreover, limited studies have been conducted in Nigeria on how PLWHA perceive their life with...

  • Initial Virologic Response and HIV Drug Resistance Among HIV-Infected Individuals Initiating First-line Antiretroviral Therapy at 2 Clinics in Chennai and Mumbai, India. Hingankar, Nitin K.; Thorat, Smita R.; Deshpande, Alaka; Rajasekaran, S.; Chandrasekar, C.; Kumar, Suria; Srikantiah, Padmini; Chaturbhuj, Devidas N.; Datkar, Sharda R.; Deshmukh, Pravin S.; Kulkarni, Smita S.; Sane, Suvarna; Reddy, D. C. S.; Garg, Renu; Jordan, Michael R.; Kabra, Sandhya; Tripathy, Srikanth P.; Paranjape, Ramesh S. // Clinical Infectious Diseases;May2012 Supplement 4, Vol. 54 Issue suppl_4, pS348 

    Human immunodeficiency virus drug resistance (HIVDR) in cohorts of patients initiating antiretroviral therapy (ART) at clinics in Chennai and Mumbai, India, was assessed following World Health Organization (WHO) guidelines. Twelve months after ART initiation, 75% and 64.6% of participants at the...

  • Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naïve HIV-2–Infected Patients: The ACHIEV2E Collaboration Study Group. Benard, Antoine; van Sighem, Ard; Taieb, Audrey; Valadas, Emilia; Ruelle, Jean; Soriano, Vicente; Calmy, Alexandra; Balotta, Claudia; Damond, Florence; Brun-Vezinet, Françoise; Chene, Geneviève; Matheron, Sophie // Clinical Infectious Diseases;May2011, Vol. 52 Issue 10, p1257 

    This European inter-cohort collaboration shows poorer immunological and virological responses with triple NRTI compared to PI/r-containing cART in treatment-naïve HIV-2-infected patients, regardless of baseline CD4 cell count. PI/r-containing cART should be recommended as first-line...

  • HIV guideline changes could slow virus spread.  // New Scientist;12/5/2009, Vol. 204 Issue 2737, p7 

    The article reports on the advice issued by the World Health Organization (WHO) to administer antiretroviral therapy (ART) to people with human immunodeficiency virus (HIV) earlier in the infection cycle. WHO suggests that ART be started when the levels of CD4 immune cells decreased below 200...

  • WHO's use of generic antiretrovirals needs support.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p2 

    Presents information on a program implemented by the World Health Organization to increase access to antiretrovirals for HIV-infected individuals in developing countries. Efforts to prove the bioequivalence of generic and brand-name antiretrovirals; Criticism of various international agencies...

  • Antiretroviral access increased but still room for improvement.  // PharmacoEconomics & Outcomes News;4/8/2006, Issue 500, p26 

    According to the latest report issued by the WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS), the number of patients with HIV infections in low and middle income countries who are receiving antiretroviral (ART) treatments has increased from 400 000 in December 2003 to 1.3 million...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics